MedTrace Logo

Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension

NCT00403650 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-04-12

No results posted yet for this study

Summary

This trial will study the treatment of sarcoidosis-associated pulmonary arterial hypertension with inhaled iloprost, a drug approved for primary pulmonary arterial hypertension.

Conditions

Interventions

DRUG

Iloprost

Iloprost 2.5-5 mg inhaled via nebulizer up to 6 times a day

Sponsors & Collaborators

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Robert P. Baughman, MD · University of Cincinnati

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-07-31
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00403650 on ClinicalTrials.gov